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Evidence based management of hypertension
Using cardiovascular risk profiles to individualise
hypertensive treatment
Michael Pignone, Cynthia D Mulrow
Individual risks must be assessed in order to for the
best decision to be made as to which patients to treat
and how. Assessment identifies important cardiovas-
cular risk factors that may warrant treatment and helps
to establish the absolute benefits that patients can
expect from particular treatments. The benefits of
treating hypertensive patients also vary, depending on
each patient’s competing risks of dying from other
than cardiovascular causes. For example, patients with
multiple serious conditions, such as end stage
Alzheimer’s disease, obstructive lung disease, frequent
falls, gout, and urinary incontinence, have high
competing risks that may minimise or negate the ben-
efits of treating their hypertension.
Factors useful in helping patients
prioritise their treatments
Establishing treatment priorities for patients with mul-
tiple cardiovascular risk factors and multiple condi-
tions is difficult. Factors such as those given in the box
deserve consideration. Knowing and weighing up mul-
tiple risk factors, conditions, and treatments is difficult.
Explaining them to patients is daunting and time con-
suming. Some patients prefer to be told what to do
rather than to have to take in the diverse, complicated
information necessary to make their own or joint
informed decisions; others prefer a great deal of infor-
mation. We recommend informed decision making,
with attention to the factors given in the box, when
possible.
Table 1 Approximate reductions in relative risk associated with various treatments for
hypertensive people with other cardiovascular risk factors but no known cardiovascular
disease
Treatment
Approximate change (%) in relative risk (range)
Death Cardiovascular disease
Angiotensin converting enzyme inhibitor (ramipril) −15 (−25 to −5) −20 (−30 to −15)
Antiglycaemic drugs Not shown Not shown
Antihypertensive drugs 10 (5 to −10) −30 (−40 to −15)
Antilipidaemic drugs −5 (−20 to 10) −30 (−40 to −20)
Aspirin −5 (−15 to 5) −15 (−30 to −5)
Physical activity Unclear Unclear
Smoking cessation Unclear; >−20 Unclear; <−50
Summary points
Several treatment options reduce risk of
cardiovascular disease and improve outcomes in
patients with hypertension
Providers should consider the expected benefits
and potential adverse effects of different
treatment options and discuss them with patients
The use of decision tools may help decision
making about options for reducing cardiovascular
risk
Factors helpful in prioritising patients’
treatments
• Type, immediacy, and magnitude of expected
benefits and harms
• Availability and costs of treatments
• Feasibility and likelihood of compliance
• Competing risks from various conditions
• Expected interactions with other treatments
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Patients with no known cardiovascular disease
Benefits that can be expected from treating patients
with hypertension and other cardiovascular risk factors
but no known cardiovascular disease include fewer
deaths, longer survival times, and less fatal and
non-fatal cardiovascular disease, such as myocardial
infarction and stroke. Table 1 shows the approximate
magnitude of such benefits in people without known
cardiovascular disease. The magnitude of risk reduc-
tion for cardiovascular disease is similar for treatment
with antihypertensive or lipid lowering drugs; it is
slightly lower for aspirin prophylaxis. Both the type
and magnitude of benefits that can be expected from
lifestyle modifications, such as exercising more or quit-
ting smoking, are less clear.
Some treatments, such as aspirin, are immediately
beneficial, while others, such as lipid lowering, may take
a year or more to take effect. There are no data on the
effects of long term use, for over 10 years, of any of the
interventions listed. Finally, some of the possibilities,
such as quitting smoking, have other benefits that are
not shown, including decreased risk of lung cancer and
respiratory disease.
Patients with known cardiovascular disease
Patients with hypertension and known cardiovascular
disease are at high risk of future cardiovascular events
and warrant aggressive management of their risk
factors. Several different effective treatments, which are
discussed in Evidence-Based Hypertension1 and the third
paper in this series,2 are available. Table 2 shows
approximate risk reductions that can be expected with
different treatments for patients with known cardio-
vascular disease.
Priorities and sequencing of treatments
We have found few data on synergy between different
treatments. We usually give treatment of high risks
such as extreme hypertension or extremely high lipid
concentrations priority over treatment of mildly
abnormal levels of these or other risk factors. We have
no profound suggestions for fail safe methods for
helping patients to decide the priorities and sequenc-
ing of their various treatments. Decisions about which
treatments should be combined, and the order in
which they should be initiated, depend on
x Types of benefits that are of greatest interest to
patients
x Patients’ individual risk profiles and accompanying
conditions, and their modifiability
x The magnitude of potential benefits from possible
treatments
x The types and frequencies of harms that may
accompany particular treatments
x The availability, complexity, feasibility, and costs of
particular treatments
x Whether patients think they are ready to adhere to
particular treatments
x The degree of certainty or uncertainty of assess-
ments.
When faced with patients with multiple risk factors
and conditions, we use the above principles to guide
our discussions about which treatments should be tried
and when. Where possible, we use balance sheets and
decision aids, such as the sample shown in the figure, to
Table 2 Approximate reductions of relative risk associated with various treatments for
hypertensive people with other cardiovascular risk factors and known cardiovascular
disease
Treatment
Approximate change (%) in relative risk (range)
Death Cardiovascular disease
Angiotensin conversting enzyme inhibitor (ramipril) −15 (−25 to −5) -20 (−30 to −15)
Antiglycaemia drugs Not shown Not shown
Antilipidaemia drugs* −20 (−30 to −10) −30 (−40 to −20)
Aspirin −15 (−20 to −10) −25 (−40 to −10)
â blockers −25 (−30 to −15) −25 (−40 to −10)
Cardiac rehabilitation −25 (−40 to −10) −25 (−40 to −10)
Fish oil −15 (−25 to −5) −10 (−20 to 0)
Mediterranean diet −30 (−80 to −10) −30 (−85 to −45)
Smoking cessation Unclear; >-20 Unclear; <-50
*Applies primarily to statin treatment for raised concentrations of low density lipoprotein and total
cholesterol. Treatment with fibrates for near normal concentrations of low density lipoprotein and total
cholesterol, but low concentrations of high density lipoprotein cholesterol, has shown risk reductions of















Mr. Singh, your risk of having a cardiovascular event, such as a stroke or heart attack, in the next five
years is about 25%. By comparison, an 85-year-old man with no risk factors has about a 15% chance of
having such events in the next five years.
The graph shows your risk.
Five-year risk for cardiovascular events
A number of treatments are available to you that may help prevent future cardiovascular problems.
Some are listed below:
Risk of heart attack or stroke after adding blood pressure medication
Taking medication to lower your blood pressure reduces your chance of having a heart attack or stroke,
and several medications are available for this purpose. On average, these medications lower the chance
of having a heart attack or stroke by about 30%. The graph below shows your own chance of having a
heart attack or stroke would decrease from about 25% to about 15%. They also reduce the chance of
developing heart failure - a condition in which your heart does not pump the blood well, causing
swelling in the legs and shortness of breath - by 50%.
Several different medications are available for treating hypertension. Your choice of medications will
depend on many factors, including cost and side effects of the medications and the presence of other
illnesses that may be helped or worsened by the medication used to treat high blood pressure.
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Sample decision tool for a patient without cardiovascular disease
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guide discussions. As the data suggest that the relative
risk reductions achievable with particular therapies are
generally independent of underlying cardiovascular
risk levels, we base projections of absolute benefits of
treatments on patients’ individual risk profiles. Thus,
patients at higher risk stand to gain more from
treatment over the next 5-10 years than patients at
lower risk, and the benefits of their treatments are less
likely to be offset by other harms. We try to reach
agreement with patients about what constitutes
sufficient risk to warrant starting or adding additional
treatment.
To help prioritise treatments for patients without
known cardiovascular disease, we try to estimate the
amount of risk associated with each of the patient’s risk
factors and accompanying conditions, using tools such
as those described in Evidence-Based Hypertension and in
the second article in this series.3 We tie our estimate of
benefit from a particular therapy to our estimate of risk
from a particular factor or condition. For example, we
postulate that a patient with especially abnormal levels
of a risk factor, such as severe hypertension, may ben-
efit more from having his or her hypertension treated
than by taking aspirin.
We also inform patients about the types of benefits
and harms that they can expect from particular
treatments. For example, primary prevention trials
show that aspirin and lipid lowering statins reduce risk
of coronary heart disease but probably not stroke.
Aspirin is much less expensive than statins, but it has
more potential adverse effects, such as gastrointestinal
bleeding. Some patients’ choices between using aspirin
or a statin may depend on cost as well as their
perceived risks of adverse effects. Other patients’
choices may depend more on their perceived benefits
of treatments. For example, some patients may prefer
to stop smoking rather than taking either aspirin or a
statin, because of perceived multiple benefits of
stopping smoking and fewer perceived benefits from
the drug. Other patients may feel that they are not
ready or able to quit smoking, but willing to take drugs.
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Correction
Bovine spongiform encephalopathy and variant Creutzfeldt-Jakob
disease
Several errors occurred in this paper by Paul Brown
(7 April, pp 841-4). In the sixth paragraph, the values given
in lines 2 and 6 should read 10 LD50/g [not 1 LD50/g], and










When I use a word . . .
Re: re-
I have been asked why I used the word “reduplication”
in a piece about dilatation (BMJ 2000;320:625), when
“duplication” would have done just as well. Now it is
true that the first definition of reduplication in the
Oxford English Dictionary is “the action of doubling or
folding,” which is just what duplication means.
However, “reduplication” has a distinct grammatical
meaning, not shared by “duplication”: “repetition of a
syllable or letter, especially in the case of verbal forms.”
Typically this occurs in the perfect tense of Greek and
Latin verbs. For example, the paradigm of the Latin
word to touch is tango, tangere, tetigi, tactum, with
reduplication in the perfect tense, mimicking the
repetition of a past action.
A reduplication is also “a word form produced by
repetition of a syllable.” Examples include
helter-skelter, gaga, hurdy-gurdy, tip-top. In some
languages reduplication is simply used to indicate a
plural, but there are other uses. For example, it can
indicate intensity, as in beri-beri, which is probably
from the Sinhalese word beri (debility)—that is, much
debility. Or repetition, as in the onomatopoeic
borborygmi (multiple rumbling of the guts). Or
continuity, as in murmur and susurrus.
Japanese is rich in reduplications, and some medical
examples have been imported into English. Itai-itai is
painful osteomalacia secondary to cadmium induced
nephropathy; it means ouch-ouch, an example of the
onomatopoeic use of reduplication, as in ding-dong
and bow-wow. Moya-moya disease, a cause of stroke in
young people, is occlusion of the internal carotid
arteries or of arteries in the circle of Willis, causing a
collateral circulation, responsible for the typical
angiographic pattern, which resembles a puff of smoke
(moya-moya in Japanese); the term has also been used
to describe fuzzy echoes seen during
echocardiography.
Reduplicated words, such as those above, are also
called reiterative words. Reiterate also seems to contain
a redundant re-. To iterate means to repeat or go over
again; to reiterate means to go over again and again.
But the latter has displaced the former in general use.
Another word for all this reduplication, palillogy,
comes from the Greek word ðáëé́õ (palin), meaning
back or again. But perhaps the best is frequentative
(adjective and noun). Coming as it does from frequent,
you might expect it to be frequentive, but the
reduplication in the middle makes the point.
Jeff Aronson clinical pharmacologist, Oxford
We welcome articles of up to 600 words on topics such
as A memorable patient, A paper that changed my practice,
My most unfortunate mistake, or any other piece
conveying instruction, pathos, or humour. If possible
the article should be supplied on a disk. Permission is
needed from the patient or a relative if an identifiable
patient is referred to. We also welcome contributions
for “Endpieces,” consisting of quotations of up to 80
words (but most are considerably shorter) from any
source, ancient or modern, which have appealed to the
reader.
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